questionText: To ask the Secretary of State for Health and Social Care, with reference to the draft guidance published by NICE entitled Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis, published on 3 November 2023, whether she has made an assessment of the potential impact of the recommendation that modular therapies should not be provided on the NHS on the health of people with cystic fibrosis.
answerText: The National Institute for Health and Care Excellence (NICE) has recently consulted on its draft recommendations on the use of lumacaftor–ivacaftor (Orkambi), tezacaftor–ivacaftor (Symkevi) and ivacaftor–tezacaftor–elexacaftor (Kaftrio) and has not yet pu...
heading: Cystic Fibrosis: Drugs